Annuncio pubblicitario
Italia markets close in 3 hours 30 minutes

  • FTSE MIB

    34.197,90
    -73,22 (-0,21%)
     

  • Dow Jones

    38.460,92
    -42,77 (-0,11%)
     

  • Nasdaq

    15.712,75
    +16,11 (+0,10%)
     

  • Nikkei 225

    37.628,48
    -831,60 (-2,16%)
     

  • Petrolio

    82,96
    +0,15 (+0,18%)
     

  • Bitcoin EUR

    59.574,26
    -2.540,82 (-4,09%)
     

  • CMC Crypto 200

    1.358,12
    -24,45 (-1,77%)
     

  • Oro

    2.341,70
    +3,30 (+0,14%)
     

  • EUR/USD

    1,0722
    +0,0021 (+0,19%)
     

  • S&P 500

    5.071,63
    +1,08 (+0,02%)
     

  • HANG SENG

    17.284,54
    +83,27 (+0,48%)
     

  • Euro Stoxx 50

    4.950,58
    -39,30 (-0,79%)
     

  • EUR/GBP

    0,8566
    -0,0016 (-0,19%)
     

  • EUR/CHF

    0,9790
    +0,0006 (+0,06%)
     

  • EUR/CAD

    1,4656
    +0,0001 (+0,00%)
     

Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference

Bioventus, Inc.
·1 minuto per la lettura
Bioventus, Inc.
Bioventus, Inc.

DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET).

The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
dave.crawford@bioventus.com